Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2146170> ?p ?o }
Showing triples 1 to 98 of
98
with 100 triples per page.
- Q2146170 subject Q18924462.
- Q2146170 subject Q7108202.
- Q2146170 subject Q8788406.
- Q2146170 subject Q8788974.
- Q2146170 subject Q9052323.
- Q2146170 abstract "Retigabine (INN) or ezogabine (USAN), codenamed D-23129, is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011. Retigabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain.".
- Q2146170 atcPrefix "N03".
- Q2146170 atcSuffix "AX21".
- Q2146170 bioavailability "60.0".
- Q2146170 casNumber "150812-12-7".
- Q2146170 fdaUniiCode "12G01I6BBU".
- Q2146170 iupacName "ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate".
- Q2146170 pubchem "121892".
- Q2146170 thumbnail Retigabine2DCSD.svg?width=300.
- Q2146170 wikiPageExternalLink pmidlookup?view=long&pmid=10220491.
- Q2146170 wikiPageExternalLink neurology.jsp.
- Q2146170 wikiPageExternalLink Retigabine.
- Q2146170 wikiPageWikiLink Q1077823.
- Q2146170 wikiPageWikiLink Q10916362.
- Q2146170 wikiPageWikiLink Q1124842.
- Q2146170 wikiPageWikiLink Q11269508.
- Q2146170 wikiPageWikiLink Q1163287.
- Q2146170 wikiPageWikiLink Q130146.
- Q2146170 wikiPageWikiLink Q1332167.
- Q2146170 wikiPageWikiLink Q133823.
- Q2146170 wikiPageWikiLink Q1340863.
- Q2146170 wikiPageWikiLink Q1366695.
- Q2146170 wikiPageWikiLink Q1368197.
- Q2146170 wikiPageWikiLink Q1436668.
- Q2146170 wikiPageWikiLink Q1700871.
- Q2146170 wikiPageWikiLink Q1714245.
- Q2146170 wikiPageWikiLink Q1722307.
- Q2146170 wikiPageWikiLink Q1741970.
- Q2146170 wikiPageWikiLink Q18924462.
- Q2146170 wikiPageWikiLink Q192309.
- Q2146170 wikiPageWikiLink Q204711.
- Q2146170 wikiPageWikiLink Q21163344.
- Q2146170 wikiPageWikiLink Q212322.
- Q2146170 wikiPageWikiLink Q213433.
- Q2146170 wikiPageWikiLink Q213907.
- Q2146170 wikiPageWikiLink Q2198549.
- Q2146170 wikiPageWikiLink Q223907.
- Q2146170 wikiPageWikiLink Q225957.
- Q2146170 wikiPageWikiLink Q2370000.
- Q2146170 wikiPageWikiLink Q30.
- Q2146170 wikiPageWikiLink Q30612.
- Q2146170 wikiPageWikiLink Q3271540.
- Q2146170 wikiPageWikiLink Q338924.
- Q2146170 wikiPageWikiLink Q390239.
- Q2146170 wikiPageWikiLink Q407693.
- Q2146170 wikiPageWikiLink Q410346.
- Q2146170 wikiPageWikiLink Q410400.
- Q2146170 wikiPageWikiLink Q410412.
- Q2146170 wikiPageWikiLink Q412391.
- Q2146170 wikiPageWikiLink Q415403.
- Q2146170 wikiPageWikiLink Q41571.
- Q2146170 wikiPageWikiLink Q416602.
- Q2146170 wikiPageWikiLink Q422222.
- Q2146170 wikiPageWikiLink Q425265.
- Q2146170 wikiPageWikiLink Q45959.
- Q2146170 wikiPageWikiLink Q461809.
- Q2146170 wikiPageWikiLink Q4926095.
- Q2146170 wikiPageWikiLink Q576618.
- Q2146170 wikiPageWikiLink Q608510.
- Q2146170 wikiPageWikiLink Q622899.
- Q2146170 wikiPageWikiLink Q632856.
- Q2146170 wikiPageWikiLink Q686886.
- Q2146170 wikiPageWikiLink Q7108202.
- Q2146170 wikiPageWikiLink Q7140388.
- Q2146170 wikiPageWikiLink Q718753.
- Q2146170 wikiPageWikiLink Q7239206.
- Q2146170 wikiPageWikiLink Q775940.
- Q2146170 wikiPageWikiLink Q7817.
- Q2146170 wikiPageWikiLink Q7825858.
- Q2146170 wikiPageWikiLink Q796604.
- Q2146170 wikiPageWikiLink Q824258.
- Q2146170 wikiPageWikiLink Q8788406.
- Q2146170 wikiPageWikiLink Q8788974.
- Q2146170 wikiPageWikiLink Q901125.
- Q2146170 wikiPageWikiLink Q9052323.
- Q2146170 wikiPageWikiLink Q928770.
- Q2146170 wikiPageWikiLink Q9368.
- Q2146170 wikiPageWikiLink Q9377.
- Q2146170 atcPrefix "N03".
- Q2146170 atcSuffix "AX21".
- Q2146170 bioavailability "60.0".
- Q2146170 casNumber "150812".
- Q2146170 iupacName "ethyl N-[2-amino-4-[methylamino]phenyl]carbamate".
- Q2146170 pubchem "121892".
- Q2146170 unii "12".
- Q2146170 type ChemicalSubstance.
- Q2146170 type Drug.
- Q2146170 type ChemicalObject.
- Q2146170 type Thing.
- Q2146170 type Q8386.
- Q2146170 comment "Retigabine (INN) or ezogabine (USAN), codenamed D-23129, is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011.".
- Q2146170 label "Retigabine".
- Q2146170 depiction Retigabine2DCSD.svg.